PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel Madrid, May 11th , 2020- PharmaMar (MSE:PHM) has announced today a licensing agreement with Megapharm Ltd. to commercialize the marine-derived anticancer drug lurbinectedin in Israel. The Parties agreed not to disclose the financials details. PharmaMar will retain exclusive production rights and will sell the product to Megapharm for commercial use. Lurbinectedin?s New Drug Application (NDA) is currently being evaluated by the FDA under ?Priority Review? status, seeking accelerated approval in the US for the treatment of patients with Small Cell Lung Cancer (SCLC) who have progressed after prior platinum-containing therapy. The FDA has set a PDUFA target action date of August 16, 2020. According to Luis Mora, Managing Director of PharmaMar?s Oncology Business Unit, ?this is our third strategic agreement with Megapharm and we are very happy with our business partner. This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.? Megapharm CEO, Miron Drucker said, ?we are very pleased to have our third licensing deal with PharmaMar. This licensing deal will not only strengthen our existing strong relationship with PharmaMar and demonstrate our high confidence in PharmaMar`s development pipeline, but also strengthen Megapharm's oncology portfolio in the Israeli market.? Legal Statement This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. About Lurbinectedin Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets. About PharmaMar Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis? in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com. About Megapharm Ltd. Megapharm Ltd. is a leading Israeli private pharma marketing company, founded in 1989, exclusively representing a number of major American, European and Japanese pharmaceutical companies. Megapharm provides its partners with a full set of commercial capabilities, including registration, market access and sales and marketing. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in selected therapeutic areas (i.e. Oncology, Hematology, CNS, Orphan and metabolic drugs) and a proven track record for obtaining national reimbursement and inclusion of its products in Health Funds in Israel. Additional information can be found at: www.megapharm.co.il Media Contact: Alfonso Ort?n ? Communications Director aortin@pharmamar.com Mobile: +34 609493127 Miguel Mart?nez-Cava ? Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464 Phone: +34 918466000 Capital Markets & Investor Relations: Jos? Luis Moreno ? Capital Markets & Investor Relations Director investorrelations@pharmamar.com Phone: +34 914444500 Or please visit our website at www.pharmamar.com